- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- April 2023
- 109 Pages
Global
€3384EUR$3,500USD£2,908GBP
- Report
- January 2021
- 137 Pages
China, Global
From €3000EUR$3,324USD£2,669GBP
Ciclesonide is a corticosteroid used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is administered as an inhalation aerosol or dry powder inhaler. Ciclesonide works by reducing inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath. It is also used to prevent asthma attacks.
Ciclesonide is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2006. It is available in both generic and brand-name formulations. The brand-name formulation, Alvesco, is manufactured by Teva Pharmaceuticals.
The ciclesonide market is a growing segment of the respiratory drugs market. It is used to treat a wide range of respiratory diseases, and is increasingly being prescribed as a first-line treatment for asthma. It is also being used in combination with other drugs to treat COPD.
Companies in the ciclesonide market include Teva Pharmaceuticals, Mylan, Sandoz, and Sun Pharmaceuticals. Show Less Read more